LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the August 7, 2017 deadline in the class action lawsuit filed on behalf of investors who purchased Roche Holding AG (“Roche” or the “Company”) (OTC: RHHBY) securities between March 2, 2017 through June 5, 2017, inclusive (the “Class Period”). Roche investors have until August 7, 2017 to file a lead plaintiff motion. To obtain information or participate in the class action, please visit the Roche case page on our website at www.glancylaw.com/case/roche-holding-ag.
On June 5, 2017, news reports stated that a new study showed that adding Roche’s breast cancer drug Perjeta to its older treatment Herceptin only had a slight benefit, while more than doubling the one-year treatment cost; and that the combination of Perjeta with Herceptin had higher rates of certain side effects than Herceptin alone, including severe diarrhea.
In addition, also on June 5, 2017, an investigation by STAT revealed that Roche’s rheumatoid arthritis drug Actemra has been associated with heart attacks, strokes and heart failure at least as often as some competing drugs despite not carrying the same warnings in its prescribing information. Following this news, Roche shares fell $1.75 per share, or over 5%, to close at $34.14 per share. The complaint filed in this lawsuit alleges that Roche misled investors regarding the Company’s profitability of Roche’s products.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased shares of Roche during the Class Period you may move the Court no later than August 7, 2017 to ask the Court to appoint you as lead. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.